Manina Medtech, Vall d’Hebron spin-off, closes an investment round to develop a medical device to increase the success of In Vitro Fertilization
Summary
Manina Medtech, Vall dHebron spin-off, has just closed its first round of pre-seed financing with Medex Partner as the lead Investor in the developing of a medical device to be used at the point-of-care. This capital increase will enable the company to perform clinical research in patients undergoing in vitro fertilization (IVF) cycles.Currently, 190 million people and one in six couples worldwide are affected by infertility, making them seek help in Assisted Reproduction Treatments. It has a sensor attached to a transfer catheter that detects a biomarker, which, together with a technology supported by artificial intelligence, determines whether the uterus is in the ideal conditions for successful embryo implantation on the day of testing. The AEMPS (Agencia Espa\xf1ola de Medicamentos y Productos Sanitarios) and Vall dHebron ethics committee have authorized the study to begin the research in the coming weeks. The company will also expand the team by adding experts in IT, regulatory legislation, and clinical research.SEEDCHRONY will represent a substantial change in the embryo transfer procedure and allow the uterine readiness evaluation immediately, avoiding biopsies and preserving the endometrial tissue.